Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

24.7%

22 terminated/withdrawn out of 89 trials

Success Rate

73.8%

-12.7% vs industry average

Late-Stage Pipeline

39%

35 trials in Phase 3/4

Results Transparency

0 of 62 completed trials have results

Key Signals

21 terminated

Enrollment Performance

Analytics

Phase 3

31(38.3%)

Phase 2

30(37.0%)

N/A

10(12.3%)

Phase 1

6(7.4%)

Phase 4

4(4.9%)

81Total

Phase 3(31)

Phase 2(30)

N/A(10)

Phase 1(6)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (89)

Showing 20 of 89 trials

NCT02210130Completed

The Microvascular Brain Retina And Kidney Study

Role: collaborator

NCT00148837Phase 2Completed

Efficacy of Prazosin Versus Placebo Associated With Peg-interferon Alpha 2b and Ribavirin in Chronic Hepatitis C With Genotype 1 or 4 and Severe Fibrosis

Role: lead

NCT01413152Not ApplicableCompleted

Residual Risk Assessment Of HIV Transmission

Role: lead

NCT03671291Not ApplicableCompleted

Missed Opportunities to Pre-exposure Prophylaxis for HIV Infection on Person Newly Diagnosed With HIV

Role: lead

NCT01164462Not ApplicableCompleted

Feasibility and Limitations of Offering Community Based Rapid HIV Testing to Men Who Have Sex With Men (MSM)

Role: lead

NCT00115609Phase 3Completed

Efficacy of Tenofovir-Emtricitabine and Efavirenz in HIV Infected Patients With Tuberculosis (ANRS129)

Role: lead

NCT00113282Phase 2Completed

Efficacy of Adding Interleukin-2 to an Optimized Antiretroviral Regimen in HIV Patients in Therapeutic Failure (ANRS123)

Role: lead

NCT00120367Phase 2Completed

Early Intensification of Antiretroviral Therapy Including Enfuvirtide in HIV-1-Related Progressive Multifocal Leucoencephalopathy (ANRS125)

Role: lead

NCT00122603Phase 2Completed

Dual Boosted Protease Inhibitor Regimens Without Any Additional Antiretroviral Therapy in HIV-1 Infected Patients (ANRS127)

Role: lead

NCT00536627Phase 1Completed

Efficacy and Tolerance of Naked DNA Vaccine in Patients With Chronic B Hepatitis

Role: lead

NCT00823342Phase 3Terminated

ANRS HB 05 Multicenter Study Evaluating Efficacy and Safety of Clevudine Monotherapy Versus Tenofovir Monotherapy Versus Combination Therapy of Clevudine and Tenofovir for 96 Weeks in HBeAg Negative Patients With Chronic Hepatitis B, naïve to Anti-VHB Therapy

Role: lead

NCT03459768Unknown

Cohort Study on People Who Inject Drugs in Senegal

Role: lead

NCT03235310Unknown

Prospective Observational Cohort Study on Mother to Child Transmission HIV1/HIV2 and Prevention

Role: lead

NCT01269632Not ApplicableCompleted

Cohort of Young Adults Infected With HIV Since Birth or During Childhood

Role: lead

NCT04468724Not ApplicableUnknown

MAKASI Intervention for African and Caribbean Migrants' Empowerment in Sexual Health in Paris Greater Area

Role: lead

NCT03661203Unknown

Investigation of the Psychosocial Factors Responsible for the Late Recourse to HIV Testing Within MSM

Role: lead

NCT01213927Unknown

National Cohort of Uncomplicated Alcoholic Cirrhosis

Role: collaborator

NCT01426243Phase 3Completed

The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient.

Role: lead

NCT00796770Phase 1Completed

Vaccination of HIV-1 Infected Patients With Dendritic Cells in Addition to Antiretroviral Treatment - (DALIA Trial)

Role: collaborator

NCT01039220Not ApplicableCompleted

Incidence of H1N1v Influenza-like Illness and Risk Factors for Serious Influenza Forms in HIV Infected Patients

Role: lead